Spyre Therapeutics, Inc.

SYRE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$89,423$188,893$34,863$15,142
Short-Term Investments$513,665$150,384$20,848$77,986
Receivables$0$0$375$815
Inventory$0$0$0$0
Other Curr. Assets$5,386$2,251$6,172$4,948
Total Curr. Assets$608,474$341,528$62,258$98,891
Property Plant & Equip (Net)$0$0$6,650$8,355
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$10$331$2,236$2,680
Total NC Assets$10$331$8,886$11,035
Other Assets$0$0$0$0
Total Assets$608,484$341,859$71,144$109,926
Liabilities
Payables$666$896$677$3,319
Short-Term Debt$0$0$625$436
Tax Payable$0$0$0$0
Deferred Revenue$0$0$517$2,359
Other Curr. Liab.$53,394$31,082$12,837$14,030
Total Curr. Liab.$54,060$31,978$14,656$20,144
LT Debt$0$0$4,004$4,624
Deferred Rev, NC$0$0$2,179$1,217
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$36,620$125,865$0$0
Total NC Liab.$36,620$125,865$6,183$5,841
Other Liabilities$0$0$0$0
Cap. Leases$0$0$4,629$5,060
Total Liabilities$90,680$157,843$20,839$25,985
Equity
Pref Stock$155,820$184,927$0$0
Common Stock$13$10$6$5
Retained Earnings-$972,432-$764,414-$425,624-$341,809
AOCI$180$302-$48-$20
Other Equity$1,334,223$763,191$475,971$425,765
Total Equity$517,804$184,016$50,305$83,941
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$608,484$341,859$71,144$109,926
Net Debt-$89,423-$188,893-$30,234-$10,082